-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $32

Benzinga·06/17/2026 12:20:15
Listen to the news
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $20 to $32.